Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.
$KYMR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/3/2025 | $79.00 | Equal-Weight → Overweight | Morgan Stanley |
6/3/2025 | $60.00 | Neutral → Buy | B. Riley Securities |
6/2/2025 | $51.00 | Neutral → Buy | BofA Securities |
5/20/2025 | $55.00 | Buy | Stifel |
3/13/2025 | $52.00 | Buy | Citigroup |
12/10/2024 | $60.00 | Buy | BTIG Research |
12/6/2024 | $55.00 | Market Perform | BMO Capital Markets |
12/2/2024 | $57.00 | Equal Weight → Overweight | Wells Fargo |